Ovid insider plans $910K sale of 325K shares

Rhea-AI Filing Summary

Ovid Therapeutics Inc. (symbol OVID) has an affiliated stockholder, Jeffrey A. Rona, filing a notice of proposed sale under Rule 144 for up to 325,000 shares of common stock, expected around 08/24/2026, to be effected through Morgan Stanley following a stock option exercise for cash.

The common stock has 195,297,857 shares outstanding. In the prior three months, Jeffrey A. Rona reported Rule 144 sales of common stock on 08/17/2026, 08/18/2026, and 08/19/2026 at disclosed share amounts and dollar values.

Key Figures

Shares to be sold under Rule 144: 325,000 shares Aggregate market value of proposed sale: $910,000 Shares outstanding: 195,297,857 shares +3 more

6 metrics

Shares to be sold under Rule 144 325,000 shares Proposed sale of Ovid Therapeutics Inc. common stock around 08/24/2026

Aggregate market value of proposed sale $910,000 Aggregate market value for 325,000 shares covered by the Rule 144 notice

Shares outstanding 195,297,857 shares Ovid Therapeutics Inc. common stock shares outstanding as stated in the filing

Sale on 08/17/2026 52,532 shares; $149,978.86 Jeffrey A. Rona sale of Ovid common stock during past three months

Sale on 08/18/2026 60,000 shares; $169,800.00 Jeffrey A. Rona sale of Ovid common stock during past three months

Sale on 08/19/2026 37,468 shares; $108,657.20 Jeffrey A. Rona sale of Ovid common stock during past three months

Key Terms

Rule 144, Affiliated Stockholder, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Affiliated Stockholder financial

"Affiliated Stockholder 144: Securities Information"

Stock Option Exercise financial

"Common Stock | 08/24/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for OVID Therapeutics Inc. (OVID)?

It discloses that Jeffrey A. Rona, an affiliated stockholder, has filed a Rule 144 notice to potentially sell up to 325,000 shares of Ovid Therapeutics Inc. common stock, expected around 08/24/2026, in connection with a stock option exercise for cash through Morgan Stanley.

How many OVID shares are proposed to be sold under this Rule 144 notice?

The notice covers a proposed sale of up to 325,000 shares of Ovid Therapeutics Inc. common stock. These shares are expected to be sold in connection with a stock option exercise for cash on or about 08/24/2026.

What is the reported aggregate market value of the OVID shares to be sold?

The filing reports an aggregate market value of $910,000 for the 325,000 shares of Ovid Therapeutics Inc. common stock covered by the proposed Rule 144 sale, with an indicated approximate sale date of 08/24/2026.

How many OVID shares are outstanding according to this filing?

The filing states that there are 195,297,857 shares of Ovid Therapeutics Inc. common stock outstanding. This figure provides context for the 325,000 shares covered by the proposed Rule 144 sale; it is a baseline figure, not the amount being sold.

What OVID stock sales has Jeffrey A. Rona reported in the past three months?

The filing lists three prior sales of Ovid common stock: 52,532 shares for $149,978.86 on 08/17/2026, 60,000 shares for $169,800.00 on 08/18/2026, and 37,468 shares for $108,657.20 on 08/19/2026.

Through which broker is the proposed OVID Rule 144 sale expected to be executed?

The proposed sale of up to 325,000 shares of Ovid Therapeutics Inc. common stock is listed as being through Morgan Stanley, with the broker identified at its 1585 Broadway, New York address in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:48 PM EDT Accepted by SEC EDGAR 08/24/2026 - 04:47 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001311404
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OVID THERAPEUTICS INC.
SEC File Number	001-38085
Address of Issuer	441 NINTH AVENUE 14TH FLOOR NEW YORK NEW YORK 10001
Phone	(646) 661-7661
Name of Person for Whose Account the Securities are To Be Sold	Jeffrey A. Rona
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliated Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley 1585 Broadway New York NY 10036	325000	910000	195297857	08/24/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/24/2026	Stock Option Exercise	Issuer			325000	08/24/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jeffrey A. Rona C/O OVID THERAPEUTICS INC. 441 NINTH AVENUE NEW YORK NY 10001	Common Stock	08/17/2026	52532	149978.86
Jeffrey A. Rona C/O OVID THERAPEUTICS INC. 441 NINTH AVENUE NEW YORK NY 10001	Common Stock	08/18/2026	60000	169800.00
Jeffrey A. Rona C/O OVID THERAPEUTICS INC. 441 NINTH AVENUE NEW YORK NY 10001	Common Stock	08/19/2026	37468	108657.20

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeffrey Rona
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)